Avila Therapeutics Presents Preclinical Data with AVL-292, its Btk Inhibitor, Demonstrating Suppression of Autoimmune Disease Activity

WASHINGTON & WALTHAM, Mass.--(BUSINESS WIRE)--Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the presentation of data on AVL-292, a clinical-stage inhibitor of Bruton's tyrosine kinase (Btk), at the 2011 Federation of Clinical Immunology Societies (FOCIS) meeting taking place on June 23-26, 2011 in Washington, DC. The data presented demonstrate that AVL-292, a potent and selective inhibitor of Btk, rapidly reduced clinical arthritis scores as well as inflammation, joint damage and bone erosion in preclinical studies in animal models.